Progression of shallow medial femoral condyle radiographic lucencies in Thoroughbred repository radiographs and their influence on future racing careers

Radiological properties of nano-hydroxyapatite compared to natural equine hydroxyapatite quantified using dual-energy CT and high-field MR

In equine medicine, assisted bone regeneration, including use of biomaterial substitutes like hydroxyapatite (HAP), is crucial for addressing bone defects. To follow-up on the outcome of HAP-based bone defect treatment, the advancement in quantified diagnostic imaging protocols is needed. This study aimed to quantify and compare the radiological properties of the HAP graft and natural equine bone using Magnetic Resonance (MR) and Computed Tomography (CT), both Single (SECT) and Dual Energy (DECT). SECT and DECT, allow for the differentiation of three HAP grain sizes, by progressive increase in relative density (RD). SECT, DECT, and MR enable the differentiation between natural cortical bone and synthetic HAP graft by augmentation in Effective Z and material density (MD) in HAP/Water, Calcium/Water, and Water/Calcium reconstructions, alongside the reduction in T2 relaxation time. The proposed quantification provided valuable radiological insights into the composition of HAP grafts, which may be useful in follow-up bone defect treatment.

Treatment Comparison for Medial Femoral Condyle Subchondral Cystic Lesions and Prognosis in Yearling Thoroughbred Racehorse Prospects

Subchondral cystic lesions (SCL) in the medial femoral condyle are a usual finding in Thoroughbred survey and auction repository radiographs. Several treatments with different outcomes have been studied over the years to improve soundness and racing prognosis. Our objective was to report the racing prognosis in Thoroughbred yearlings intended for racing that were diagnosed with SCL in the medial femoral condyle and were treated using four current and different techniques: intralesional injection of corticosteroids, SCL debridement through the joint with a drill bit, translesional cortical screw placement, and absorbable hydroxyapatite implant placement. Data from 182 Thoroughbred yearlings treated for SCL in the medial femoral condyle were collected from 2014 to 2020. Limb affected, age at surgery, sex, and radiographic measurements of the SCL were recorded. Auction price and racing performance were collected for treated horses and compared to 154 maternal siblings free of medial femoral condyle SCL. Analyses were conducted to assess if racing prognosis was affected by SCL size, to detect differences in auction price and selected flat racing outcome parameters between cases and controls, and to compare racing prognosis between the studied treatments. Mares and lesions located in the right stifle were significantly overrepresented. The auction price of treated horses was significantly lower than that of their siblings. Horses treated for SCL had significantly lower chances to start in a race than controls (59% vs. 74% respectively). Wider SCL negatively affected the chances to start at least in one race, and negatively affected the earnings made in the 2-year-olds' racing year. Horses with SCL treated using a bioabsorbable implant had a significantly higher median in starts as 3-year-olds (seven starts) than horses that had the SCL debrided with a drill bit (three starts). In conclusion, Thoroughbred yearlings treated for a medial femoral condyle SCL had lower auction prices and decreased ability to start a race compared to siblings' wider cysts had worse prognosis to start a race and might affect earnings as 2-year-olds; and horses treated with bioabsorbable composite implant placement had more starts as 3-year-olds than with other techniques.

Equine subchondral lucencies: Knowledge from the medial femoral condyle

Equine subchondral lucencies (SCL) have been described since the first availability of suitable radiographic equipment. The initial clinical sign can be lameness, but SCLs are often first found on surveys of juvenile horses and are primarily a radiographic concern for public auctions. When lameness is present, it varies from subtle to obvious and can be intermittent. Some SCLs heal spontaneously, and some remain blemishes, but when the SCL and lameness are persistent, further damage to the joint and limitations to an athletic career are likely. SCLs were initially described in the distal limb followed by the stifle, and the medial femoral condyle (MFC) is now considered the most common location. The aim of this review is to highlight the initial pathology and discuss the clinical and experimental information available on equine SCLs. SCL treatment has evolved from rest alone and has progressed to debridement, grafting, intralesional injection, and most recently, transcondylar screw and absorbable implant placement. Comparison of success rates between techniques is difficult due to variations in follow-up and outcome measures, and no single technique is best for all SCLs. Treatment appears to increase success by 15%-20% over rest alone, but the method chosen depends on many factors. This review emphasizes the need for further work to fully understand SCL formation and all aspects of trabecular bone healing to optimize surgical therapy and improve treatment success.

Subchondral lucencies of the medial femoral condyle in yearling and 2-year-old Thoroughbred sales horses: Prevalence, progression and associations with racing performance

BACKGROUND

Subchondral lucencies (SCLs) in the distal aspect of the medial femoral condyle (MFC) of young Thoroughbred horses are a source of controversy on presale radiographs. There is limited scientific evidence regarding the risk of progression and impact on future racing performance.

OBJECTIVES

To (1) identify the prevalence of MFC SCLs on sales repository radiographs in yearling and 2-year-old Thoroughbreds; (2) identify any association between grade of MFC SCL and future racing performance and (3) monitor changes in MFC SCL grades between yearling and 2-year-old sales.

STUDY DESIGN

Prospective cohort study.

METHODS

Radiographs were obtained with consignor permission from a 2016 yearling sale and five 2017 2-year-old sales. Stifle radiographs were evaluated and MFC SCLs graded on a scale of 0-3. Axial MFC lucencies were recorded separately. Maximum MFC grades per horse were analysed for associations with racing performance outcomes, adjusted for sex, to the end of the horses' 4-year-old racing year. Analysis was via logistic, negative binomial or linear regression as appropriate, with the threshold for significance set at α = 0.05.

RESULTS

Radiographs from 2508 yearlings (5016 stifles) and 436 2-year-olds (872 stifles) were included in the study. MFC SCLs of grades 1-3 were observed in 242 (9.65%) yearlings and 49 (11.2%) 2-year-olds. Bilateral MFC SCLs of grades 1-3 were observed in 54 (2.2%) yearlings and 12 (2.8%) 2-year-olds. Grade 1 MFC SCLs in yearlings either remained unchanged (14/31), progressed to a grade 2 (6/31) or resolved (11/31) by the 2-year-old sale. Grade 2 MFC SCLs in yearlings remained unchanged (6/10), progressed to a grade 3 (2/10) or improved to a grade 1 (2/10). Yearlings with a grade 3 MFC SCL had a 78% probability of starting a race (95% confidence interval [CI] 58.2-89.6%), compared with an 84% probability of racing for grade 0 yearlings (95% CI 82.7-85.8%). Six of the seven yearlings with axial MFC lucencies raced.

MAIN LIMITATIONS

This study may underestimate the prevalence of severe lesions in the general yearling population of U.S. Thoroughbreds. However, the convenience sample used is representative of the population of interest at sales. The study design could not address exclusions prior to sale.

CONCLUSIONS

Grade 1 MFC SCLs are the most common type seen in yearling and 2-year-old sales horses. The majority of yearling grade 1 MFC SCLs resolved or remained static by 2-year-old sales. It was also possible for grade 2 and 3 MFC SCLs to improve one grade between sales. Fewer sales yearlings with a grade 3 MFC SCL raced, but in those that did race there was no evidence of worse performance compared to unaffected peers. Axial MFC lucencies did not affect racing performance.

Treatments and Prognosis for Subchondral Cystic Lesions in the Distal Extremities in Thoroughbred Prospect Racehorses

Subchondral cystic lesions (SCLs) in equines and their treatments have been mainly studied in the medial femoral condyle of the femur. SCLs in the distal extremities affecting the fetlock or interphalangeal joints are frequent, but treatment or prognosis studies in horses are currently sparse. Our objective was to compare four treatments for SCLs in the distal extremities (intralesional injection of corticosteroids, transcortical drilling, cortical screw placement, and absorbable hydroxyapatite implant placement) and report the racing prognoses for affected thoroughbred yearlings. Data from 113 thoroughbred yearlings treated for SCLs in the distal extremities were collected from 2014 to 2020. Age at surgery, sex, bone affected, radiographic SCL measurements, SCL shape, and type of treatment were recorded. Sale data and racing performance were collected for the operated horses and for 109 maternal siblings that were free of SCLs. An analysis was conducted to assess if SCL size affected racing prognosis and to detect differences in sale value and selected racing parameters between the cases and controls. The outcomes for the different treatments, the different bones affected, and the SCL shape type were also analyzed. There was no difference in the ability to start in a race between the cases and controls (60.2% vs. 69.7%, respectively). The auction value of the treated horses was significantly lower than that of their siblings. The bone affected did not impact any of the racing variables studied, whereas the height of the SCLs negatively affected the number of wins and placed races. The type of treatment for the horses affected by SCLs did not have an impact on sale prices, ability to start a race, race starts, wins, and places, or age at the time of the first start. In conclusion, yearlings diagnosed with an SCL in the distal extremities had lower auction prices and decreased racing performances, with lower numbers of wins correlated with larger SCL heights compared to the siblings. Similar racing performance was found regardless of the treatment received.

Comparative results of 3 treatments for medial femoral condyle subchondral cystic lesions in Thoroughbred racehorses

OBJECTIVES

To compare 3 different methods for treatment of medial femoral condyle (MFC) subchondral cystic lesions in Thoroughbred horses <24 months old based on the criterion of ability to race post-treatment.

STUDY DESIGN

Retrospective cohort study.

ANIMALS

Thoroughbreds (n = 107, age < 24 months) diagnosed with MFC subchondral cystic lesions.

METHODS

Medical records between January 2004 and December 2017 were reviewed. Three treatment methods were used in these horses during that time frame: arthroscopic debridement, intralesional autologous mesenchymal stem cell (MSC) injection, and intralesional corticosteroid injection. The outcome evaluated was the ability to compete in a pari-mutuel race.

RESULTS

Seventy-eight of 107 Thoroughbreds (73%) raced post-treatment; 41/57 (72%) of horses treated by arthroscopic debridement raced; 16/19 (84%) of horses treated with intralesional MSCs raced; 21/31 (68%) of horses treated with intralesional corticosteroids raced. There was no difference between groups in the ability to start a race. Sex, limb affected, and lesion size also had no effect on the ability to start a race. There was a trend for increasing lesion size reducing the probability of racing.

CONCLUSIONS

Seventy-three percent of the horses raced, but there was no difference in the ability of unraced Thoroughbreds to race after treatment of MFC subchondral cystic lesions with arthroscopic debridement, intralesional mesenchymal stem cells, or intralesional corticosteroids.

CLINICAL SIGNIFICANCE

The 3 reported treatment options may be considered for treatment of MFC subchondral cystic lesions with a good prognosis for racing post-treatment. Owners should be advised that increasing lesion size decreases the probability of racing.

Osteoclast density is not increased in bone adjacent to radiolucencies (cysts) in juvenile equine medial femoral condyles

BACKGROUND

There is a knowledge gap about how equine MFC subchondral radiolucencies (SR) arise and evolve. Osteoclasts are believed to have a role but have not been studied in situ.

OBJECTIVES

To measure and compare osteoclast density and the percentage of chondroclasts in healthy and MFC SR specimens from juvenile Thoroughbreds.

STUDY DESIGN

Cadaveric study.

METHODS

Medial femoral condyles (MFC) from a tissue bank of equine stifles were studied. Inclusion criteria were MFCs (≤8 months old) with a computed tomography SR lesion and histological focal failure of endochondral ossification (L group). Contralateral, lesion-free, MFCs were a control group (CC). Osteochondral slabs were cut through the lesion (L), a healthy site immediately caudal to the lesion, (internal control; IC) and the contralateral, site-matched controls (CC). Histological sections were immunostained with Cathepsin K for osteoclast counting. Osteoclasts in contact with the growth cartilage (chondroclasts) were also counted. The sections were segmented into regions of interest (ROI) at different depths in the subchondral bone: ROI₁ (0-1 mm), ROI₂ (1-3 mm) and ROI₃ (3-6 mm). Osteoclasts were counted and the bone area was measured in each ROI to calculate their density. Chondroclasts were counted in ROI₁ .

RESULTS

Sections were studied from L and IC (n = 6) and CC sites (n = 5). Osteoclast density was significantly higher in ROI₁ when compared with ROI₃ in all groups. Although higher osteoclast density was measured in ROI₁ in the L group, no significant differences were detected when compared with control ROIs. The proportion of chondroclasts in ROI₁ was lower in the L sections when compared with controls but no significant differences were detected.

MAIN LIMITATIONS

Limited sample size.

CONCLUSIONS

Osteoclasts are important actors in MFC subchondral bone development, digesting both growth cartilage (chondroclasts) and bone, but the pathophysiology of early MFC SRs cannot be explained solely by an increased osteoclast presence in the subchondral bone.

Microstructural features of subchondral radiolucent lesions in the medial femoral condyle of juvenile Thoroughbreds: A microcomputed tomography and histological analysis

BACKGROUND

The aetiology of equine medial femoral condyle (MFC) subchondral bone radiolucencies (SR) is unknown.

OBJECTIVES

Characterise the microstructural structural features of MFC SR in juvenile Thoroughbreds with microcomputed tomography (μCT) and histology.

STUDY DESIGN

Cross-sectional post-mortem study.

METHODS

Distal femurs were collected at post-mortem. Conventional tomodensitometry was employed to scout for MFCs with and without SR lesions (SR+ and SR-, respectively). Group 1 were CT MFC SR+ and Group 2 age-matched SR- controls. Both underwent μCT and histological analysis. Group 3 CT MFC SR- foals, <6 months, were selected to search for chondronecrosis. Histological sections, processed from the lesion (Group 1) and a corresponding site in Groups 2 and 3, were assessed for chondronecrosis, fibrin, fibroplasia and osteochondral separation. Group 3 sections were surveyed for chondronecrosis alone.

RESULTS

A total of 178 femurs from 89 Thoroughbreds were harvested. Of these horses 19.1% (95% CI: 10.9%-27.3%) were CT MFC SR+ (17/23; 7.46 ± 4.36 months) and met the inclusion criteria for Group 1. Group 2 included 30 CT MFC SR- specimens (5.00 ± 2.73 months) and Group 3 had 44 CT MFC SR- s (2.68 ± 1.74 months). SR were located axially in foals <7 months of age, and centrally thereafter. All SRs had areas of thickened cartilage on histology and separation at the osteochondral junction containing fibrin (acute event) and fibroplasia (chronicity) in 73.9% (17/23; 95% CI: 56%-91.9%). In Group 1 specimens, chondronecrosis was present in 82.6% (19/23; 95% CI: 67.1%-98.1%) but four MFC SR+ had no evidence of chondronecrosis. Chondronecrosis was not detected in the Group 3 foal MFCs.

MAIN LIMITATIONS

No longitudinal follow-up.

CONCLUSIONS

The absence of chondronecrosis, pathognomic of osteochondrosis, in four MFC SR+s and in all of the CT MFC SR- foals suggests that osteochondrosis is not the cause, or the only cause, of these lesions and favours trauma as an alternate aetiological hypothesis.

A composite absorbable implant used to treat subchondral bone cysts in 38 horses

BACKGROUND

In the last 30 years, several treatments have been proposed to treat subchondral cystic lesions (SCLs) but there have been no randomised studies to compare different methods and there is no consensus as to the optimal treatment.

OBJECTIVES

To evaluate a biocompatible absorbable implant for the treatment of SCLs in young horses in different anatomical locations.

STUDY DESIGN

Retrospective case series.

METHODS

Horses with SCLs were treated with debridement through a trans-cortical extra-articular approach and an absorbable implant was inserted in the cavity. Clinical and radiographic follow-up was recorded and follow up ranged from 28 to 46 months (mean 37 months). Racing records were reviewed.

RESULTS

Thirty-eight horses between 10 and 24 months of age were included in the study. In 36 of 38 horses treated, lameness resolved, and 77% average filling of the cyst was measured 120 days after surgery on radiographs. In two cases, surgical complications were recorded.

MAIN LIMITATIONS

Information about the resorption of the implant is not available. Radiographs were performed in various hospitals or at farms or training stables, therefore, possible minor variations in technique and positioning occurred.

CONCLUSIONS

The extra-articular approach to the SCLs followed by the insertion of the absorbable implant led to clinical and radiographic improvement of the SCLs at 120 days after surgery. This technique, feasible in different anatomical locations, may offer an alternative to treat SCLs in young horses.